Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Authors
Keywords
-
Journal
Biomolecules & Therapeutics
Volume 23, Issue 6, Pages 493-509
Publisher
The Korean Society of Applied Pharmacology
Online
2015-10-22
DOI
10.4062/biomolther.2015.116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration
- (2014) Yang Chen et al. INTERNATIONAL JOURNAL OF CANCER
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
- (2012) Gerhard Moldenhauer et al. JNCI-Journal of the National Cancer Institute
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Site-specific chemical protein conjugation using genetically encoded aldehyde tags
- (2012) David Rabuka et al. Nature Protocols
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
- (2011) Brenda A. Kellogg et al. BIOCONJUGATE CHEMISTRY
- Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I
- (2011) George A. Ellestad CHIRALITY
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- CD30: an important new target in hematologic malignancies
- (2011) Yehuda E. Deutsch et al. LEUKEMIA & LYMPHOMA
- World Antibody Drug Conjugate Summit Europe
- (2011) Alain Beck et al. mAbs
- Proteolytic networks in cancer
- (2011) Steven D. Mason et al. TRENDS IN CELL BIOLOGY
- Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
- (2010) Simone Jeger et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
- (2010) Hans-Peter Gerber BIOCHEMICAL PHARMACOLOGY
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Molecularly Defined Antibody Conjugation through a Selenocysteine Interface
- (2009) Thomas Hofer et al. BIOCHEMISTRY
- Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection
- (2009) Elizabeth Boeggeman et al. BIOCONJUGATE CHEMISTRY
- Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- (2009) D. Dornan et al. BLOOD
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
- (2009) Travis S. Young et al. JOURNAL OF MOLECULAR BIOLOGY
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
- (2008) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
- (2008) Jagath R. Junutula et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Anti-CD30 diabody-drug conjugates with potent antitumor activity
- (2008) K. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- (2008) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now